HeartCare Medical-B Announces 2026 Business Targets, Core Product Registrations, and Clinical Milestones for Brain-Computer Interface Technology

Economic Observer NetworkHeartCare (06609.HK) announced its operating targets for 2026 and progress in multiple core businesses.

Company Performance Goals

The company announced its 2026 business targets on February 7, 2026, planning annual revenue of no less than 540 million yuan and profit of no less than 100 million yuan, highlighting confidence in performance growth.

Product Development Progress

The registration application for the self-developed self-expanding intracranial drug-eluting stent was accepted by the National Medical Products Administration in January 2026. It is expected to complete the certification by the end of 2026, potentially becoming the world's first product of its kind. Meanwhile, products such as coils are expected to receive overseas market certification in the first quarter of 2026, accelerating international expansion.

Business Progress

The interventional brain-computer interface project has completed technical validation, with the first human clinical trial expected to commence in 2026 and registration application submission planned for 2028, laying the foundation for innovative breakthroughs in the field of neuromodulation.

Strategic Advancement

The company plans to apply for the STAR Market listing in 2026 based on its 2025 financial data and has currently entered the listing tutoring phase. If successful, it will enhance the liquidity of the capital platform.

The above content is based on publicly available information and does not constitute investment advice.